Zim Laboratories Share Price | Zim Laboratories Stock Screener
ZIMLAB
Pharmaceuticals
Share Price NSE
₹104.65
▼
-4.64 (-4.25%)
Share Price BSE
₹123.85
▼
-3.90 (-3.05%)
As of May 12, 2026, the Zim Laboratories share price (NSE: ZIMLAB) is ₹104.65 on NSE and ₹123.85 on BSE, down 4.25% from the previous close, with shares trading between ₹101.20 and ₹112.80, and a 52-week range of ₹60.26–₹120.82.
Check ZIMLAB annual price range for the annual price range and momentum.
Use the Zim Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Zim Laboratories Market Cap
₹652.17 Cr.
ZIMLAB P/E Ratio (TTM)
115.05
Zim Laboratories P/B Ratio
2.29
EPS (TTM)
₹0.76
Dividend Yield
-
Debt to Equity
0.45
ZIMLAB 52 Week High
₹120.82
Zim Laboratories 52 Week Low
₹60.26
Operating Margin
7.00%
Profit Margin
3.60%
ZIMLAB Revenue (TTM)
₹111.00
EBITDA
₹13.00
Net Income
₹4.00
Total Assets
-
Total Equity
-
Zim Laboratories Share Price Chart
Screen Zim Laboratories share price with an interactive chart. Analyse ZIMLAB price trends and volatility across different timeframes.
Zim Laboratories Company Profile - Fundamental Screener
Screen Zim Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ZIMLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE518E01015
Zim Laboratories Balance Sheet Screener
Screen ZIMLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 0 | 0 | 447 | 342 | 342 | 325 | 325 | 329 | 298 | 259 |
| Current Assets | 0 | 0 | 228 | 191 | 212 | 192 | 182 | 194 | 173 | 154 |
| Fixed Assets | 0 | 0 | 161 | 109 | 106 | 107 | 116 | 106 | 94 | 89 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 49 | 30 | 20 | 22 | 28 | 22 | 20 | 28 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 0 | 0 | 239 | 200 | 176 | 161 | 154 | 151 | 137 | 118 |
| Share Capital | 0 | 0 | 49 | 49 | 16 | 16 | 16 | 16 | 8 | 8 |
| Reserves & Surplus | 0 | 0 | 190 | 152 | 160 | 145 | 138 | 135 | 129 | 110 |
Zim Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Zim Laboratories income statement and profit fundamentals.
Analyze ZIMLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Zim Laboratories share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111 | 110 | 73 | 91 | 110 | 119 | 83 | 94 | 98 | 106 | 69 | 87 | 97 | 107 | 95 |
| Expenses | 98 | 94 | 68 | 83 | 96 | 102 | 74 | 83 | 85 | 90 | 63 | 77 | 85 | 90 | 82 |
| EBITDA | 13 | 16 | 6 | 8 | 15 | 17 | 9 | 11 | 13 | 16 | 6 | 11 | 13 | 16 | 13 |
| Operating Profit % | 7.00% | 13.00% | 6.00% | 6.00% | 12.00% | 13.00% | 10.00% | 10.00% | 12.00% | 15.00% | 7.00% | 11.00% | 12.00% | 14.00% | 12.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 1 | 1 |
| Profit Before Tax | 5 | 8 | -2 | 0 | 6 | 11 | 1 | 3 | 6 | 10 | 0 | 5 | 7 | 11 | 8 |
| Tax | 1 | 3 | -1 | 0 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 4 | 2 |
| Net Profit | 4 | 5 | -2 | 0 | 4 | 8 | 1 | 2 | 4 | 7 | 0 | 4 | 5 | 7 | 5 |
| EPS | 0.76 | 1.01 | -0.38 | -0.09 | 0.90 | 1.66 | 0.18 | 0.49 | 0.82 | 1.48 | 0.05 | 0.85 | 0.98 | 4.33 | 3.17 |
Zim Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen ZIMLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 50 | 41 | 16 | 38 | 49 | 32 | 22 | 35 | 37 | 32 |
| Investing Activities | -55 | -40 | -73 | -36 | -14 | -6 | -19 | -21 | -26 | -7 |
| Financing Activities | 28 | -9 | 60 | 1 | -33 | -26 | -2 | -15 | -10 | -25 |
| Net Cash Flow | 23 | -8 | 3 | 3 | 2 | 0 | 1 | -1 | 1 | 0 |
Zim Laboratories Shareholding Pattern Screener
See Zim Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Zim Laboratories promoter holding and ownership changes for ZIMLAB on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 30.34% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% |
| FII Holding | 0.00% | 0.01% | 0.03% | 0.00% | 0.02% | 0.01% | 0.00% | 0.00% |
| DII Holding | 0.07% | 0.24% | 0.24% | 0.24% | 0.20% | 0.00% | 0.11% | 0.10% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.77% | 47.78% | 47.50% | 48.20% | 36.63% | 49.01% | 49.21% | 45.48% |
| Other Holding | 36.81% | 18.71% | 18.96% | 18.30% | 29.89% | 17.72% | 17.42% | 21.15% |
| Shareholder Count | 16,762 | 17,448 | 16,641 | 17,282 | 17,251 | 17,100 | 17,483 | 17,716 |
Zim Laboratories Share Dividend Screener - Share Yield Analysis
Check Zim Laboratories dividend history with payout and yield data.
View Zim Laboratories dividend details including ex-dates and amounts for ZIMLAB stock.
Zim Laboratories Stock Index Membership
See which indices include Zim Laboratories stock.
Check ZIMLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Zim Laboratories Market Events Screener - Corporate Actions
Get Zim Laboratories corporate actions including splits, bonuses, and buybacks.
Check Zim Laboratories stock events that may affect ZIMLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-06-29 | 2026-06-29 | Annual General Meeting | NA | 16.53% |
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | -10.75% |
| 2026-02-16 | 2026-02-16 | Extraordinary General Meeting | NA | -5.66% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 7.74% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 5.86% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -29.01% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 27.77% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 5.18% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 5.61% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 5.94% |
| 2024-06-27 | 2024-06-27 | Annual General Meeting | NA | 2.64% |
| 2022-12-22 | 2022-12-22 | Bonus | 2:1 | 5.37% |
| 2022-06-29 | 2022-06-29 | Extraordinary General Meeting | NA | -18.24% |
| 2018-10-04 | Bonus | 1:1 | - |
Zim Laboratories Competitors Screener - Peer Comparison
Screen ZIMLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,196 | 38.85 | 58,220 | 6.38% | 11,565 | 65.65 |
| Divis Laboratories | 179,112 | 70.14 | 10,560 | 8.73% | 2,520 | 54.67 |
| Torrent Pharmaceuticals | 152,778 | 70.56 | 13,886 | 20.34% | 2,138 | 56.91 |
| Cipla | 115,763 | 29.61 | 29,045 | 2.24% | 3,870 | 64.19 |
| Zydus Life Science | 111,913 | 21.30 | 26,720 | 13.65% | 5,242 | 66.01 |
| Dr Reddys Laboratories | 108,612 | 25.92 | 33,593 | -0.44% | 3,998 | 56.75 |
| Lupin | 107,762 | 19.97 | 27,488 | 19.98% | 5,345 | 62.58 |
| Mankind Pharma | 104,382 | 54.06 | 14,278 | 12.03% | 1,750 | 66.83 |
| Aurobindo Pharma | 89,107 | 24.74 | 33,385 | 3.21% | 3,376 | 64.69 |
| Laurus Labs | 79,953 | 87.15 | 6,868 | 22.01% | 890 | 72.60 |
Zim Laboratories Company Announcements - News Screener
Screen ZIMLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-20 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-05 | Letter Sent To Members | - |
| 2026-06-05 | Reg. 34 (1) Annual Report. | - |
| 2026-06-05 | The Notice Of 42Nd Annual General Meeting For The F.Y 2025-26 | - |
| 2026-06-05 | Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-19 | Earnings Presentation Q4 & FY26 | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-19 | Results - Financial Results For 31.03.2026 | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-19 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 19.05.2026 | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-12 | Board Meeting Intimation for Consideration And Approval Of The Audited Standalone And Consolidated Financial Results For The Year Eneded 31St March 2026. | - |